Nycomed Amersham has signed a five-year, nonexclusive agreement to distribute Theragenics’ TheraSeed palladium-101 brachytherapy seed. Princeton, NJ-based Nycomed will gain rights to distribute TheraSeed in the U.S., Canada, and Puerto Rico, according to Theragenics of Buford, GA.
TheraSeed is a rice-sized device used in the treatment of localized prostate cancer, according to Theragenics. For Nycomed, the deal will allow the contrast company to offer both its own iodine-based seed (OncoSeed) as well as a palladium-based seed (TheraSeed) for prostate cancer treatment, according to John Jeans, president of Nycomed Amersham Therapy Products.
By AuntMinnie.com staff writersSeptember 20, 2000
Related Reading
Nycomed Amersham spin signal contrast technology enters clinical trials, August 23, 2000
Nycomed inks deal with Premier for prostate brachytherapy, August 3, 2000
Nycomed Amersham joins Global Healthcare Exchange, July 26, 2000
Contrast study favors Nycomed agent in coronary procedures, May 10, 2000
Nycomed spotlights OncoSeed study, May 4, 2000
Copyright © 2000 AuntMinnie.com
